argenx: Leadership Continuity and Pipeline Milestones Underpin Sustained Buy Rating and $1,006 Price Target

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Argenx Se, with a price target of $1,006.00.

Tazeen Ahmad has given his Buy rating due to a combination of factors tied to both leadership continuity and strategic execution. Tazeen Ahmad’s rating is based on confidence that the planned CEO transition to Karen Massey will preserve and further strengthen Argenx’s commercial momentum, especially given her central role in the successful rollout of Vyvgart and her prior experience at leading pharmaceutical and consulting firms. The continued involvement of outgoing CEO Tim Van Hauwermeiren as non-executive director and board chair is seen as mitigating transition risk and maintaining the company’s strategic direction. Management’s reiterated commitment to its Vision 2030 strategy, centered on expanding the Vyvgart franchise and delivering on the near-term pipeline, underpins expectations for sustained value creation.
In addition, Ahmad emphasizes that 2026 should be a particularly eventful year, with several pivotal data readouts across key indications that could significantly broaden Vyvgart’s market and support the advancement of the next pipeline-in-a-product, empasiprubart. The prior proof-of-concept results in these programs increase conviction that at least some of the upcoming trials will succeed, providing multiple opportunities for upside. Further early-stage milestones, including phase 2 and phase 1 data for additional assets and a planned registrational trial, reinforce the depth and diversification of Argenx’s pipeline. Taken together with the maintained price objective of $1,006 and the stock’s status as one of the firm’s top picks for 2026, these elements justify sustaining a Buy recommendation.

In another report released today, Citi also maintained a Buy rating on the stock with a $1,124.00 price target.